A detailed history of Exodus Point Capital Management, LP transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 29,552 shares of GALT stock, worth $80,381. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,552
Holding current value
$80,381
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.04 - $2.86 $60,286 - $84,518
29,552 New
29,552 $81,000
Q3 2021

Nov 15, 2021

SELL
$2.59 - $4.15 $108,888 - $174,474
-42,042 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.07 - $5.1 $87,026 - $214,414
42,042 New
42,042 $135,000
Q2 2019

Aug 14, 2019

SELL
$3.61 - $5.0 $255,782 - $354,270
-70,854 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$3.86 - $6.02 $139,940 - $218,249
36,254 Added 104.78%
70,854 $362,000
Q4 2018

Feb 14, 2019

BUY
$3.43 - $5.74 $118,678 - $198,604
34,600 New
34,600 $119,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $162M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.